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Вackground and aim: Inﬂiximab is effective in the induction and maintenance of remission in Crohn's
disease. Whether, the perioperative administration of anti-TNF-a compromises intestinal healing leading
to anastomotic failure and increased risk of postoperative complications, remains controversial. The aim
of the study was to evaluate the effect of Inﬂiximab on intestinal anastomosis healing.Methods: Fifty six
wistar rats were divided into 4 groups: (a) 20 rats were subjected to excision of part of the terminal ileum
followed by anastomosis which was evaluated on the 3rd or 7th postoperative day; (b) 20 rats received
Inﬂiximab and thereafter, the same surgical protocol as group (a) was followed; (c) 8 rats received
Inﬂiximab and served as relative control group; and (d) 8 served as absolute control group.
Bursting pressure was used for testing intestinal healing. Additionally, the anastomoses were exam-
ined macroscopically, histologically and immunohistochemically for TGFb1, MMP1, MMP2 and Collagen
V. The results were conﬁrmed by Western blot analysis. Results: There were no signiﬁcant differences in
bursting pressures and septic intra-abdominal events among non-Inﬂiximab (a) and Inﬂiximab-treated
(b) groups. Inﬂiximab-treated (b) group showed mild to moderate inﬂammation, whereas the non-
Inﬂiximab (a) group exhibited severe inﬂammation. Expression of TGFb1, MMP2 and collagen V was
signiﬁcantly higher in the Inﬂiximab-treated (b) group. Conclusion: Inﬂiximab seems to inﬂuence in-
testinal healing in terms of less inﬂammatory activity and higher tissue remodeling activity.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.urgery, School of Medicine,
6 Vassilisis Soﬁa's Ave, 11528
by Elsevier Ltd. All rights reserved1. Introduction
The healing of the digestive anastomosis has been a subject of
interest in surgery for many decades. Healing is a complex process
depending on multiple intrinsic and extrinsic factors (i.e. the gen-
eral condition of the patient [1], tissue oxygenation and perfusion
[2], the presence of tension along the anastomosis line, peritoneal.
Table 1
Animal group's description.




Number of rats 20 20 8 8
IFX administration No days 0, 3, 6, 9, 12 days 0, 3, 6, 9, 12 No
Partial excision of ileumeanastomosis Yes Yes e 3 days after completion of
IFX administration
e e
Time of anastomoses resectioneSacriﬁce 3rd or 7th post e operative day 3rd or 7th post e operative day As group b After acclimatization
Macroscopic evaluation of anastomoses Yes Yes e e
Bursting pressure measurement Yes Yes Yes Yes
Histological evaluation Yes Yes Yes Yes
Immunohistochemical evaluation Yes Yes Yes Yes
e e
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corticosteroids, antineoplastic drugs, anti-inﬂammatory drugs can
also affect healing [5,6].
Inﬂiximab (IFX) is a chimeric IgG1 monoclonal antibody tar-
geted at human tumor necrosis factor-alpha (TNF-a), a pro-
inﬂammatory cytokine important in the pathogenesis of the in-
ﬂammatory bowel diseases (IBD) [7]. TNF-a is an inﬂammatory
mediator, which regulates the margination and cytotoxicity of
polymorphonuclear cells, is implicated in pathway of the collagen
synthesis and also provides metabolic substrate for the healing of
wounds during the inﬂammatory phase [8]. IFX, reduces the
pharmacological activity of TNF-a and can act as a moderator for
the process of inﬂammation and collagen deposition [9].
Anti-TNF-a antibodies such as IFX are currently available and
result in its neutralization [10]. Many studies have proven that IFX
treatment is effective in the management of patients with Crohn's
disease (CD) [11e14]. Apart from the therapeutic beneﬁts deriving
from TNF-a neutralization, amendments in the cellular functions
of the immune system may induce immunosuppressive effects
resulting in a potent inhibitory outcome on wound healing. This
hypothesis raises great concerns about the safety of perioperative
administration of anti-TNFs. In view of this, several studies in the
literature [15,16] have attempted to address the issue of post-
operative complications in patients with CD who have received
anti-TNF treatment in the perioperative period and reported
impaired healing after treatment with IFX, but other studies
suggested better healing of chronic wounds with the use of IFX
[17,18].
Since this issue is the subject of controversy, the aim of the
present study was to investigate the impact of perioperative
administration of IFX on the process of intestinal anastomosis
healing in rats.
2. Materials and methods
2.1. Ethics
The experiments were conducted in the Experimental e
Research Center of ELPEN (European code EL 09 BIO 03) and were
approved by the veterinary authorities of East Attica Region in
accordance with the Greek law No 160/91 in accordance to the
European Community regulations. All the guidelines of FELASA
(Federation of Laboratory Animal Science Associations) for experi-
mentation on small animals were followed. The study was
approved by the animal ethics committee of University of Athens.
2.2. Rat experimental model
The rats were randomly allocated in 4 groups: In group (a) 20
rats were subjected to excision of part of the terminal ileum, 4 cmproximally to the ileocaecal valve, followed by an end-to-end hand
sewn anastomosis, using 7/0 Nylon interrupted sutures. After re-
covery from anesthesia the rats were randomized in two groups
and were followed up until the 3rd or the 7th postoperative day. At
the end of the follow up period theywere subjected to a laparotomy
and the anastomosis, including 3 cm of small intestine proximally
and distally was resected. Following resection the animals were
sacriﬁced. Twenty animals were allocated to group (b) and after
receiving IFX (according to the IFX administration protocol) they
were subjected to the same protocol as group (a) animals. Group (c)
comprised of 8 rats that received IFX (according to the IFX
administration protocol) and no other intervention was made to
them, serving as the relative control group and 8 more rats were
allocated to group (d) which served as absolute control group and
no intervention was made to them. Groups are summarized in
Table 1.
The resected specimens were used to deﬁne the anastomotic
bursting pressure and afterwards divided into portions. One
portion of the anastomosis was immediately ﬁxed in 4% para-
formaldehyde and the other was frozen at 80 C. Anastomotic
complications were assessed macroscopically and any septic com-
plications were recorded. Anastomotic integrity, the presence of
edema, peritonitis, intra-abdominal abscess formation, adhesions
and inﬂammation were recorded.
2.3. IFX administration protocol
IFX was administered with subcutaneous injections of 5 mg/kg
inﬂiximab on days 0, 3, 6, 9, 12 and underwent surgery 3 days after
the completion of administration.
2.4. Bursting pressure measurement
Two catheters were placed into the lumen through each end of
the excised intestine. Both ends were occluded with sutures.
Normal saline was administered at 5 ml/min rate with an infusion
pump while the pressure within the lumen was continuously
monitored via the transducer of a pressure monitoring system
connected to the other catheter. The bursting pressure was deﬁned
as the pressure at which leakage of saline or gross rupture was
noted and corresponded to maximum pressure before a sudden fall
in pressure was seen.
2.5. Histopathological and immunohistochemical assessment
protocol
A 2 cm-long segment of ileus including the anastomotic site was
sampled from each animal, was ﬁxed in 10% buffered formalin for
48 h, and was submitted for histological examination. Four-cm
thick parafﬁn sections were prepared from each parafﬁn block
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with hematoxylin-eosin (H&E). The histological and immunohis-
tochemical assessment were performed by a “blinded” observer, a
pathologist who was unaware of the study groups. Inﬂammatory
reaction was assessed semiquantitatively as mild ¼ þ,
moderate ¼ þþ or severe ¼ þþþ. Parafﬁn-embedded sections of
tissues biopsied on the 7th postoperative day were stained for TGF-
b1 (1:100; Acris antibodies, AP06350PU-N), MMP1 (1:150; Novus
biologicals, NBP1-72209), MMP2 (1:200; Acris antibodies,
AM00257AF-N) and collagen V (1:150; Acris antibodies, AF6110)
antibodies. Slides were deparafﬁnized in xylene and rehydrated in a
graded alcohol series before endogenous peroxidase activity was
blocked with 3% H2O2. Indirect immunoperoxidase staining on
tissue sections was performed using the Vectastain Elite kit (Vector
Labs), according to the manufacturer's instructions. Sections were
incubated with primary antibody, overnight in a humidiﬁed
chamber at 4 C. The sections were washed 3 times with PBS, and
then a biotinylated secondary antibody was added and incubated
for 30 min at room temperature. The signal visualization was per-
formed using DAB chromogen for 2e3 min. The expression of
immunohistochemical parameters was classiﬁed by two indepen-
dent blinded observers who used a modiﬁed semi-quantitative
immunoreactivity score (IRS) according to the method of
Remmele and Stegner (1987). Intensity of staining was scored as 1
(negative), 2 (weak), 3 (medium), and 4 (intensive), whereby
additional scores of 1 (0%), 2 (<10%), 3 (10e50%), 4 (51e80%), and 5
(81e100%) indicated the percentage of positive staining in the
anastomosis area. Multiplication of the respective intensity score
(1e4) and the respective additional score (1e5) resulted in the IRS
which ranges between 1 and 20. A Leica DM LB microscope
equipped with a digital DFC 320 camera (Leica) and N-Plan objec-
tives were employed for examination of the tissue slides and pic-
ture acquisition. Photos were takenwith the Leica Application Suite
ver 2.2 software, using automatic (software) set conditions for
image acquisition.
2.6. Western blotting protocol
Frozen biopsies were thawned and disrupted with a tissue lyser
in RIPA buffer, and total proteins were quantiﬁed using the Lowry
method. Equal concentration of proteins was loaded into an 8e12%
SDS-polyacrylamide gel and then electrotransferred. Membranes
were blocked and incubated for 16e20 h at 4 C with the corre-
sponding primary antibody. The immune complexes were detected
after incubation with the appropriate peroxidase-conjugated sec-
ondary antibody with the SuperSignalWest Pico Chemiluminescent
substrate (Pierce). Protein expression of each molecule was
expressed as relative intensity, normalized to b-actin. The primary
antibodies used in the current study were: rabbit anti-TGFb1
(1:1000; Acris antibodies, AP06350PU-N); mouse anti-MMP2
(1:1000; Acris antibodies, AM00257AF-N); mouse anti-collagen V
(1:1000; Acris antibodies, AF6110); rabbit anti-MMP1 (1:1000;
Novus biologicals, NBP1-72209); and rabbit anti-beta actin
(1:1000; Rockland antibodies & assays, 600-401-886), and the
secondary antibodies: anti-rabbit IgG HRP conjugated(1:4000,
Lifespan Biosciences, LS-C56309); and anti-mouse IgG HRP conju-
gated (1:1000, R &D Systems, HAF007).
2.7. Statistial analysis protocol
In qualitative variables analysis of variance was used in order to
determine statistical signiﬁcance when the distribution was
normal. When the distribution was not normal, when the data was
ordinal, and when standard deviations differed signiﬁcantly, the
non-parametric ManneWhitney test was used. For the comparisonof quantitative variables, in order to make the comparison more
robust in view of the relatively small sample size Fischer's exact test
was used. All calculations were carried out using SPSS 15.0 for
Windows. The level of statistical signiﬁcance was set to p < 0.05.
Data are expressed as mean ± SD.
3. Results
Six animals in total died of undetermined causes. An abdominal
evaluation was made, which did not reveal any pathology. There
was no signiﬁcant difference between the mortality rates between
groups (a) and (b) (2 vs 4 deaths, p > 0.05).
3.1. Macroscopic evidence of anastomotic failure
No signiﬁcant difference was observed between non-IFX (a)
group and IFX-treated (b) group in abscess formation and perito-
nitis rates and adhesion formation on both on the 3rd and 7th
postoperative day. Anastomotic edema was signiﬁcantly lower in
animals treated with IFX on the 3rd postoperative day (9/9 vs 4/9,
p ¼ 0.029), however, there was no difference on the 7th post-
operative day (6/9 vs 4/7, p ¼ 1) (Table 2).
3.2. Bursting pressure
Bursting pressures did not have a signiﬁcant difference among
non-IFX (a) and IFX-treated (b) groups at both 3rd (6.8 ± 7 vs
37.25 ± 38.17 mmHg, p ¼ 0,41) and 7th (104.2 ± 41.6 vs
89.8 ± 14 mmHg, p ¼ 0.42) postoperative days. Of note, bursting
pressure increased abruptly between days 3 and 7 in both groups
(a) (p ¼ 0.008) and (b) (p ¼ 0.032) and this is attributed to the
physiology of intestinal healing procedure (Fig. 1).
3.3. Histological assessment
Analysis of the H&E stained histological sections in terms of the
inﬂammatory process in the anastomosis revealed less severe in-
ﬂammatory reaction in animals treated with IFX on the 7th post-
operative day (p < 0.001), as shown in Table 2.
3.4. Immunohistochemical and Western blot analysis
Immunohistochemical analysis revealed that protein expression
of TGFb1, MMP2 and collagen V was signiﬁcantly higher in the IFX-
treated anastomosis compared to the non-IFX treated group
(p < 0.01, p < 0.05, and p < 0.05 respectively). MMP1 expressionwas
low in all cases and was not changed signiﬁcantly by IFX treatment
(Fig. 2A and B). The immunohistochemical results between non-IFX
treated and IFX treated groups were conﬁrmed by Western blot
analysis (Fig. 3A and B).
4. Discussion
It is well known that the healing process depends on physio-
logical events such as inﬂammation, angiogenesis and collagen
deposition with consequent wound contraction triggered by me-
diators such as TNF-a [19]. Several studies have reported that drugs
with anti-inﬂammatory or pro-inﬂammatory action can alter
wound healing, interfering with inﬂammation and collagen depo-
sition [20]. Concerning the anti-TNF agents, clinical studies have
reported impaired healing as an adverse effect of IFX, while other
suggest better healing of chronic wounds with topical use of IFX
[18].
The primary outcome parameter for intestinal anastomotic
healing is bursting pressure. The literature addressing the impact of
Table 2








3rd post-op day 7th post-op day 3rd post-op day 7th post-op day 3rd post-op day 7th post-op day
Anastomosis leak 3/9 (33.3%) 0/9 (0%) 3/9 (33.3%) 0/7 (0%) 1 1
Edema 9/9 (100%) 6/9 (66.7%) 4/9 (44.4%) 4/7 (57.1%) 0.029* 1
Abscesses 5/9 (55.6%) 0/9 (0%) 3/9 (33.3%) 0/7 (0%) 0.637 1
Peritonitis 2/9 (22.2%) 0/9 (0%) 1/9 (11.1%) 0/7 (0%) 1 1












* p < 0.05.
a As control groups c and d were not subjected to surgical intervention, the process of anastomotic healing was compared between groups a (non-IFX) and b (IFX-treated).
b p values are the result of comparison of control and IFX treated animals in each post-operative day.
I. Papaconstantinou et al. / International Journal of Surgery 12 (2014) 969e975972anti-TNF on wound healing process in experimental rat models is
quite poor. Lopes et al. [21] reported that perioperative adminis-
tration of IFX resulted in a decrease in the tensile strength of the
abdominal wall. However, this outcome is not comparable to our
study conclusions because of the differences in mechanics and
tension, as well as tissue discrepancy between abdominal wall and
intestinal wall [22]. Our data support that perioperative treatment
with IFX does not inﬂuence bursting pressure of intestinal anas-
tomosis. This conclusion is in accordance with the rate of post-
operative septic events that do not differ signiﬁcant between
groups.
In our study the macroscopic and histological assessment by
H&E revealed a positive effect of IFX since low to moderate
inﬂammation was observed in the animals that received IFX prior
to surgery, in comparison to severe inﬂammation in the control
group. This observation is in accordance with studies suggesting
that the inhibition of TNF production by an anti-TNF agent canFig. 1. Bursting pressure measuremdownregulate the expression of inﬂammatory cytokines and me-
diators, in intestinal tissue and sustain IBD [23,24].
An advantageous effect of IFX was observed by the immuno-
histochemical analysis and protein expression analysis of the
anastomotic region on the 7th day after surgery. Higher concen-
tration of TGFb1, MMP2 and collagen V was observed in IFX-treated
animals compared with non-IFX ones. MMP1 was low in both
groups and no differences could be observed.
Concerning TGFb1, it is well known that it plays an important
role in healing of colon anastomosis [25]. In the intestinal anasto-
mosis, TGFb1 is released from activatedmacrophages and epithelial
cells and is responsible for collagen production and strengthening
of anastomosis. Experimental studies have shown that in bowel
anastomoses, maximum production of TGFb1 molecules occurs on
postoperative day 7 with diminution of TGF-b1 levels subsequently
[25]. The beneﬁcial effect of TGFb1 on wound healing was also
supported by Spom et al. who stated that TGFb1 is a DNA-derivedent of the excised anastomosis.
Fig. 2. A. Box plots demonstrating the IRS of TGFb1, MMP1, MMP2 and collagen V protein expression in the anastomosis tissue. The results are expressed as mean ± SD; **Signiﬁcant
difference were found between IFX and þIFX groups (p < 0.01); *Signiﬁcant difference were found between IFX and þIFX groups (p < 0.05) B. Immunohistochemical staining of
TGFb1, MMP1, MMP2 and collagen V protein in colonic tissue.
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mechanism and reverses deﬁcient repair rates [26]. Regarding
MMP2, although MMPs are documented as a key factor in remod-
eling of the extracellular matrix, increased levels of MMPs were
observed in chronic wounds [27]. However, Stumpf et al. observed
increased levels of MMP1, MMP2 and MMP9 in patients with
anastomotic leakage [28]. Although the elevated expression of
MMP2 is generally recognized as an indicator of impaired healing,
our data surprisingly reveal increased expression of MMP2 in the
IFX-treated animals. Similar results were reported by Grommes
et al. [29] who indicated that even though balancing zinc deﬁciency
beneﬁts the healing of colonic anastomosis due to an increased
collagen type I/III ratio, increased expression of MMP2 was
observed supposedly impairing wound healing. The combination ofa signiﬁcantly high expression of collagen V in IFX-treated animals
and the increased expression of MMP2 in our study, might indicate
a more efﬁcient remodeling of collagens. Furthermore, we
measured only the protein expression levels and we cannot
conclude on the activity levels. In agreement to our results, Gao
et al. [30] have observed IFX-induced alterations in MMPs. They
reported increased serum levels of MMP2 in ﬁstulizing and active
CD cases by the treatment with IFX and suggested that the cause of
the increase in MMP2 might be related to the turnover of the in-
testinal tissue in CD, especially the remodeling of the ECM com-
ponents. Finally, recent data suggest that TNF-a contributes to
collagen deposition by stimulating collagen-producing myoﬁbro-
blasts through TNFR2 membrane receptors and by reducing MMP2
activity. This TNFR2 mediated TNF-a signaling seems to play a
Fig. 3. A. Western blottings showing the effect of IFX on TGFb1, MMP1, MMP2 and
collagen V protein expression. B. The results of the relative protein expression are
expressed as mean ± SD.
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CD phenotype [31]. Thus, anti-TNF administration may inhibit this
molecular axis and result in accentuating MMP2 activity.
Collagen synthesis is an essential feature of anastomotic healing
in the intestine [32]. Collagens V and XI are members of the ﬁbril-
forming class of collagens, along with collagens I, II, III, XXIV and
XXVII, and comprise a subclass of regulatory ﬁbrillar collagens that
co-assemblewith collagens I, II and III [33]. Type V collagen is found
in tissues containing type I collagen and appears to regulate the
assembly of heterotypic ﬁbers composed of both type I and type V
collagen. The increase expression of collagen V following IFX
treatment seems to improve anastomotic healing [34].
Our data suggest that pre-operative administration of IFX may
beneﬁt intestinal anastomosis healing in rats due to increased
TGFb1 and collagen V. However, the administration of IFX increased
the protein expression of MMP2 the role of which is still not clear inwound healing. Thus, further investigations are needed to clarify
the inﬂuence of IFX on intestinal healing on a moremolecular level.
Limitations of our study include a relatively small number of
experimental animals used. We tried to accommodate for this with
using statistical methods which are more robust for small sample
sizes. Another limitation of our study was that we used an anti-
TNFa that is engineered for use in humans and not in rats. How-
ever, there is no commercially available anti-TNF for use in rats. In
addition, previous studies evaluating the role of anti-TNFa in
various rat models have also used the same as we did in our
experiment [35,36].5. Conclusion
The current investigation revealed that Inﬂiximab inﬂuenced
the intestinal healing with the formation of anastomosis with less
inﬂammation and higher tissue remodeling activity. However these
histopathological and immunohistochemical amendments did not
affect signiﬁcantly the rate of intra-abdominal septic events nor the
bursting pressure level of the intestinal anastomosis in Inﬂiximab-
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